Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition)
{{output}}
Treatment of breast cancer with low expression of human epidermal growth factor receptor 2 (HER2; HER2-low) has drawn much attention in recent years. With the proven therapeutic effect of trastuzumab deruxtecan (T-DXd) in patients with HER2-low (immunohistoche... ...
